{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:08:37Z","timestamp":1789549717046,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Atrial fibrillation and coronary artery disease frequently coexist in patients undergoing percutaneous left atrial appendage occlusion (LAAO), creating a complex therapeutic setting in which prevention of device-related thrombosis, cardioembolic events, and coronary ischemic complications must be balanced against a high or prohibitive bleeding risk. The optimal post-procedural antithrombotic regimen remains uncertain, particularly in patients with previous or recent percutaneous coronary intervention or acute coronary syndrome. Methods: This narrative review examines the rationale and current evidence supporting antithrombotic therapy after LAAO and integrates these data with contemporary strategies for abbreviated or de-escalated antiplatelet therapy after coronary intervention. Results: Device-related thrombosis occurs predominantly within the first 45\u201390 days after implantation, corresponding to the period of incomplete device endothelialisation, whereas thrombotic risk after coronary stenting or acute coronary syndrome is similarly greatest during the early phase and progressively declines thereafter. This temporal overlap supports an initially protective regimen followed by early treatment simplification whenever appropriate. We propose a pragmatic framework in which treatment intensity is determined by a global bleeding\u2013thrombotic risk profile incorporating bleeding history, anaemia, comorbidities, frailty, coronary presentation, procedural complexity, and follow-up imaging. The approach includes predefined triggers for rapid de-escalation in the presence of relevant bleeding or haemoglobin decline and escalation when device-related thrombosis is detected. Conclusions: Current evidence remains heterogeneous and largely observational, the proposed algorithm should be considered a decision-support framework rather than a prescriptive pathway. Prospective randomised studies are needed to define the safest individualised regimen for patients with concomitant LAAO and coronary artery disease.<\/jats:p>","DOI":"10.3390\/jcm15187181","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:58:59Z","timestamp":1789545539000},"page":"7181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Coronary Artery Disease and Atrial Fibrillation in HighBleeding Risk: Indications and Optimal Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion"],"prefix":"10.3390","volume":"15","author":[{"given":"Alessandro","family":"Mazzapicchi","sequence":"first","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Policlinico San Marco, 24040 Osio Sotto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-8270","authenticated-orcid":false,"given":"Francesco","family":"Gallo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u201cOspedale dell\u2019Angelo\u201d, AULSS3 Serenissima, 30174 Mestre, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zanarelli","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Policlinico San Marco, 24040 Osio Sotto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Filice","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Policlinico San Marco, 24040 Osio Sotto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Trichilo","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Policlinico San Marco, 24040 Osio Sotto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5982-1669","authenticated-orcid":false,"given":"Alfonso","family":"Ielasi","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, IRCCS Ospedale Galeazzi Sant\u2019Ambrogio, 20157 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Tespili","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, IRCCS Ospedale Galeazzi Sant\u2019Ambrogio, 20157 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Grassi","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Policlinico San Marco, 24040 Osio Sotto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro Carmine","family":"Semeraro","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Policlinico San Marco, 24040 Osio Sotto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-2899","authenticated-orcid":false,"given":"Giuseppe","family":"De Luca","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, IRCCS Ospedale Galeazzi Sant\u2019Ambrogio, 20157 Milan, Italy"},{"name":"Division of Cardiology, Azienda Ospedaliera Universitaria Policlinico Gaetano Martino, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giannini","sequence":"additional","affiliation":[{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Policlinico San Marco, 24040 Osio Sotto, Italy"},{"name":"Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, IRCCS Ospedale Galeazzi Sant\u2019Ambrogio, 20157 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Bunting","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation","volume":"83","author":"Joglar","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-Related Thrombus After Left Atrial Appendage Closure","volume":"138","author":"Dukkipati","year":"2018","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jacc.2025.03.535","article-title":"3-Year Clinical Outcomes Comparing the Amulet vss Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial","volume":"86","author":"Galea","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jcin.2023.05.045","article-title":"Impact of Device Implant Depth After Left Atrial Appendage Occlusion","volume":"16","author":"Leduc","year":"2023","journal-title":"JACC. Cardiovasc. Interv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacc.2021.04.098","article-title":"Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion","volume":"78","author":"Simard","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4244\/EIJ-D-21-01010","article-title":"Device-related thrombus following left atrial appendage occlusion","volume":"18","author":"Simard","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Left Atrial Appendage Closure vss Warfarin for Atrial Fibrillation","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.hrthm.2021.06.1170","article-title":"Long-term outcomes and periprocedural safety and efficacy of percutaneous left atrial appendage closure in a United Kingdom tertiary center: An 11-year experience","volume":"18","author":"Pope","year":"2021","journal-title":"Heart Rhythm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation: The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.121.057859","article-title":"Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial","volume":"145","author":"Galea","year":"2022","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e006841","DOI":"10.1161\/CIRCEP.118.006841","article-title":"Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology","volume":"12","author":"Boersma","year":"2019","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.carrev.2025.01.002","article-title":"Safety and efficacy of a light antithrombotic regimen after left atrial appendage occlusion: Insights from the LOGIC (left atrial appendage occlusion in patients with gastrointestinal or IntraCranial bleeding) international multicenter registry","volume":"80","author":"Gallo","year":"2025","journal-title":"Cardiovasc. Revas. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4244\/EIJ-D-24-00116","article-title":"A comparison of simplified or conventional antithrombotic regimens after left atrial appendage closure in patients at high bleeding risk: The PLATEBRISK study","volume":"20","author":"Rivero","year":"2024","journal-title":"EuroIntervention"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-Dose Direct Oral Anticoagulation vs. Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial","volume":"9","author":"Freixa","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion - PubMed","volume":"14","author":"Rocca","year":"2021","journal-title":"JACC. Cardiovasc. Interv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs. 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","article-title":"Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: A MASTER DAPT trial sub-analysis","volume":"43","author":"Valgimigli","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of Ticagrelor Monotherapy vs. Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4244\/EIJ-D-22-00135","article-title":"Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: A post hoc analysis of the randomised One-Month DAPT trial","volume":"18","author":"Lee","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e015197","DOI":"10.1161\/CIRCINTERVENTIONS.124.015197","article-title":"Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial","volume":"18","author":"Ishikawa","year":"2025","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jtha.2025.07.040","article-title":"comparative analysis of HAS-BLED, ORBIT, DOAC, and AF-BLEED bleeding-risk scores in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia atrial fibrillation project III (MAFP-III) cohort","volume":"24","author":"Lip","year":"2026","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","first-page":"1144","article-title":"Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or gastrointestinal bleeding: Insights from the LOGIC (Left atrial appendage Occlusion in patients with Gastrointestinal or IntraCranial bleeding) International Multicenter Registry","volume":"101","author":"Gallo","year":"2023","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jcin.2020.06.003","article-title":"The Impact of CHA(2)DS(2)-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study","volume":"13","author":"Tarantini","year":"2020","journal-title":"JACC Cardiovasc. Inter."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","article-title":"2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force","volume":"69","author":"Doherty","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): An open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus Apixaban in Patients with Atrial Fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:39:04Z","timestamp":1789547944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":36,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187181"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187181","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}